Publications by authors named "A Foli"
Background: For the time being, tafamidis is the only approved treatment for wild-type transthyretin cardiac amyloidosis. However, benefits on all-cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age.
View Article and Find Full Text PDFBiomarker-based screening enables early detection of AL amyloidosis in intermediate/high-risk MGUS patients. Our study shows that identifying pre-symptomatic AL through biomarker longitudinal monitoring allows early treatment, leading to significant organ function recovery.
View Article and Find Full Text PDFIntroduction: Co-infection of malaria and intestinal parasitosis is the concomitant presence of two parasite species in a single human host; it is more frequent in children in many parts of the world. The objective of this study was to describe the co-infection of malaria and intestinal parasitosis in children in the health district of Kloto.
Methods: This was a prospective cross-sectional study conducted over a period of four (04) months, from February 8 to May 10, in rural health centers with laboratory facilities in the Kloto sanitary district.
Article Synopsis
- * A retrospective analysis was conducted on 811 patients from the DIAMOND study, which included a total of 1281 patients diagnosed in Italy between 2016-2021, focusing on characteristics leading to their diagnosis and calculating their respective scores.
- * Findings showed that only 1% of patients had early diagnoses, with significant differences in prognostic variable distribution based on diagnostic pathways, and both NAC and Columbia scores were linked to all-cause mortality.
Background: Early identification of immunoglobulin light-chain amyloidosis (AL) is crucial due to its rapid progression. Monoclonal light-chain (M-LC) testing is the first step in the diagnostic workup for patients with suspected cardiac amyloidosis (CA). We aimed to determine whether the time interval between the first CA suspicion and M-LC testing can be related to AL amyloidosis survival outcomes.
View Article and Find Full Text PDF